Across TCGA pan-cancer cohorts, KDM6B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated KDM6B data layer compared with 21 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KDM6B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KDM6B expression acts as an unfavorable survival marker.
LUAD are the cancer types where KDM6B mass-spec protein most reproducibly stratifies survival.